Stem Cell Clinic

TxCell to Provide CAR-Treg Update in Upcoming Cell Therapy Conferences – Business Wire (press release)

VALBONNE, France--(BUSINESS WIRE)--Regulatory News:

TxCell SA (Paris:TXCL) (FR0010127662 TXCL), a biotechnology company developing innovative, personalized cellular immunotherapies using regulatory T cells (Treg) to treat severe inflammatory and autoimmune diseases as well as transplant rejection, today announces that Stphane Boissel, CEO of TxCell, will present in upcoming cell therapy conferences.

Mr. Boissel will present an update on TxCells ENTrIA CAR-Treg platform at the 5th Alliance for Regenerative Medicine (ARM) Annual Cell & Gene Therapy Investor Day which will be held on April 27, 2017 in Boston (US). The TxCell presentation will be coupled with an interview by Joshua Schimmer, MD, Managing Director and Senior Biotech Equity Research Analyst at Piper Jaffray & Co. The presentation and interview will take place at 5:00pm local time (Harborside Room).

Mr. Boissel will also be participating to a panel discussion entitled Biotech Perspective: The opportunities of cell & gene therapy and why now? at the Investment for Advanced Therapies Summit which will be held on May 3, 2017 in London (UK). This panel discussion will take place at 9:15am local time.

In addition, Mr. Boissel and other members from TxCell will attend the International Society for Cellular Therapy (ISCT) 2017 Annual Meeting which will be held on May 3-6, 2017, in London.

About TxCell http://www.txcell.com

TxCell is a biotechnology company that develops platforms for innovative, personalized T cell immunotherapies for the treatment of severe inflammatory and autoimmune diseases with high unmet medical need. TxCell is targeting a range of autoimmune diseases (both T-cell and B-cell-mediated) including Crohns disease, lupus nephritis, bullous pemphigoid and multiple sclerosis, as well as transplant rejection.

TxCell is the only clinical-stage cellular therapy company fully dedicated to the science of regulatory T lymphocytes (Tregs). Tregs are a recently discovered T cell population for which anti-inflammatory properties have been demonstrated. Contrary to conventional approaches based on non-specific polyclonal Tregs, TxCell is exclusively developing antigen-specific Tregs. This antigen specificity may either come from genetic modifications with Chimeric Antigen Receptor (CAR) or from pre-existing Treg cell T-Cell Receptor (TCR). TxCell is developing two proprietary technology platforms, ENTrIA, which is composed of genetically-engineered Tregs, and ASTrIA, which is composed of non-modified naturally antigen-specific Tregs.

Based in Sophia-Antipolis, France, TxCell is listed on Euronext Paris and currently has 46 employees.

Next events

Financial and business conferences

5th Annual Cell & Gene Therapy Investor Day (ARM)

Scientific and medical conferences

22e congrs Nantes Actualits Transplantation (NAT)

Forward-Looking Statements - TxCell

This press release contains certain forward-looking statements relating to the business of TxCell, which shall not be considered per se as historical facts, including TxCells ability to develop, market, commercialize and achieve market acceptance for specific products, estimates for future performance and estimates regarding anticipated operating losses, future revenues, capital requirements, needs for additional financing. In addition, even if the actual results or development of TxCell are consistent with the forward-looking statements contained in this press release, those results or developments of TxCell may not be indicative of their in the future.

In some cases, you can identify forward-looking statements by words such as "could," "should," "may," "expects," "anticipates," "believes," "intends," "estimates," "aims," "targets," or similar words. Although the management of TxCell believes that these forward-looking statements are reasonably made, they are based largely on the current expectations of TxCell as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements. In particular, the expectations of TxCell could be affected by, among other things, uncertainties involved in the development of the Companys products, which may not succeed, or in the delivery of TxCells products marketing authorizations by the relevant regulatory authorities and, in general, any factor that could affects TxCell capacity to commercialize the products it develops, as well as, any other risk and uncertainties developed or identified in any public documents filed by TxCell with the AMF, included those listed in chapter 4 Risk factors of the 2015 document de rfrence (registration document) approved by the AMF on May 24, 2016 under number R.16-048 and in the section 5.1 of the update of the registration document filed with the AMF on January 24, 2107 under number D.16-0346-A01. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made in this press release will in fact be realized. Notwithstanding the compliance with article 223-1 of the General Regulation of the AMF (the information disclosed must be accurate, precise and fairly presented), TxCell is providing the information in these materials as of this press release, and disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Originally posted here:
TxCell to Provide CAR-Treg Update in Upcoming Cell Therapy Conferences - Business Wire (press release)

Cell Therapy for Stroke Treatment – Medical News Bulletin

Current treatments for ischemic stroke are very time sensitive and require resources and expertise generally only found at major stroke centers. Researchers investigated the safety and efficacy of using progenitor cell therapy to reduce ischemic stroke injury and promote recovery.

Patients who suffer strokes have small time windows to seek treatment. Waiting too long to get medical help can lead to cell death resulting in permanent deficits. Currently, intravenous tissue plasminogen activator and endovascular thrombectomies are effective treatments for restoring blood flow and limiting stroke damage; however, treatment must be reached within 6 hours of symptom presentation to be effective and are very resource and skill intensive. These treatment requirements make these forms of treatment impractical for patients in less populated areas.

Cell therapy has shown promising results for ischemic stroke treatment in animals. They are able to limit cell damage and promote patient recovery when administered in longer periods following stroke. An easily administered type of cell therapy uses adult multipotent progenitor cells, which are isolated from bone marrow and have distinct phenotypes but potential for long-term culture growth. An important note is that adult progenitor cells are universal the donor does not have to be a genetic match with the recipient, making them widely available.

In a new study published in The Lancet, Hess et al. tested the safety and efficacy of adult multipotent progenitor cells in ischemic stroke treatment. The researchers sought to find the maximum safe, well-tolerated dose of progenitor cells and to assess its efficacy. Patients who had suffered a moderately severe ischemic stroke within the past 48 hours were eligible to be included in the study. Patients were initially separated into two trial arms receiving different doses of progenitor cells or placebos, a third arm was subsequently recruited that received the highest tolerated dosage of progenitor cells. Patient assessments were conducted at day 7, 30, 90 and 365 after receiving treatment. Additionally, MRIs were completed prior to treatment, 30 days post treatment and a year post treatment. Blood tests for inflammatory biomarkers were taken prior to treatment, 2 days after treatment, a week after treatment and a month after treatment. Improvements in neurological deficits and daily functioning were considered primary outcomes.

Adult multipotent progenitor cells were well tolerated, even at the highest dose (1200 million cells). No infusion reactions or toxic effects were reported, and any general adverse effects were similar between the two groups. While there was no significant improvement for patients who received the progenitor cells as opposed to the placebo, beneficial clinical effects were observed at 1-year post-treatment. This is likely due to the administration of the cells; intravenously administered progenitor cells may have difficulty entering the brain. Thus, the benefits of the treatment are likely related to the immune system and reduction of neuroinflammatory mediators, promoting brain recovery. Reductions in inflammatory biomarkers were seen in serum tests, and researchers hypothesize a similar reduction in tissue concentrations. The study was limited by a small sample size that necessitated an expansion of treatment time inclusion from 36 to 48 hours. Further studies should be conducted with a smaller time window that may show greater efficacy.

Written By: Wesley Tin, BMSc

Read more here:
Cell Therapy for Stroke Treatment - Medical News Bulletin

Allied Physical Medicine in Dallas Joins R3 Stem Cell, Now Offering … – Benzinga

Allied Physical Medicine in Allen, Texas has joined R3 Stem Cell and is now offering regenerative stem cell procedures. The therapies are successful over 85% of the time and help patients frequently avoid the need for potentially risky surgery.

Allen, Texas (PRWEB) April 24, 2017

Allied Physical Medicine in Allen, Texas has joined R3 Stem Cell and is now offering regenerative stem cell procedures. The therapies are successful over 85% of the time and help patients frequently avoid the need for potentially risky surgery. Call (844) GET-STEM for more information and scheduling.

The regenerative treatments help the body to actually repair damaged tissue such as cartilage, tendon, ligament and bone. This is very different than past treatments with steroid which did a great job of masking pain but had no effect on tissue regeneration.

Treatments are offered by a Board Certified physician, Dr. Jordan Pastorek. The stem cell treatments are amazing for those suffering from hip, knee, shoulder and ankle arthritis along with the spine too. In addition, ligament and tendon injuries including achilles, rotator cuff, knee, plantar fasciitis benefit tremendously as well. Patients have no downtime, and receive benefit usually long term.

Said R3 Stem Cell CEO David Greene, "We are proud to be working with Allied Physical Medicine's first rate team of providers to help patients benefit from these revolutionary biologics. The goal of regenerative medicine is to help patients avoid surgery and get their active lives back, and Allied is dedicated to being at the forefront of these options!"

Patients receive the treatments in one setting, often in conjunction with active rehab exercises, laser and other modalities. The combination of additional therapies enhances the positive effects of the regenerative biologics.

Currently, Allied Physical Medicine is offering a free consultation for patients. Simply call (844) GET-STEM for the top stem cell therapy in Dallas metro today!

For more information on how R3 Stem Cell works with top practices nationwide, visit http://r3stemcell.com or call the same toll free number.

For the original version on PRWeb visit: http://www.prweb.com/releases/stem-cell-therapy/dallas-fortworth-tx/prweb14270131.htm

See original here:
Allied Physical Medicine in Dallas Joins R3 Stem Cell, Now Offering ... - Benzinga

Life Extension and Insilico Medicine Use AI to Develop Ageless Cell – WholeFoods Magazine

Fort Lauderdale, FL Life Extension has partnered with Insilico Medicine to introduce Ageless Cell, the first supplement in its GEROPROTECT line to promote healthy aging by inhibiting cellular senescence.

Cellular senescence is a natural part of the aging process where cells no longer function optimally, affecting organ function, cellular metabolism, and inflammatory response. The accumulation of these senescent cells contributes to the process of aging. The Ageless Cell supplements inhibit the effects of cellular senescence by acting as geroprotectors, or interventions aimed to increase longevity and impede the onset of age-related diseases by targeting and inhibiting senescence-inducing pathways and inhibiting the development of senescent cells.

The partnership with Insilico Medicine allowed researchers to use deep learning algorithms to comb through hundreds of studies and thousands of data points a process that could have taken decades to identify four key anti-aging nutrients: N-Acetyl-L-Cysteine (NAC), myricetin, gamma-tocotrienol, and EGCG. These compounds target pathways that are known to contribute to or protect against the development of senescent cells.

Specifically, NAC upregulates signaling pathways that protect cells against oxidative stress, which promotes cellular senescence. It also reduces pathways that promote inflammation. Myricetin regulates a family of stress-responsive signaling molecules known to regulate aging in many tissues. It also promotes cell differentiation and self-repair. Gamma tocotrienol modulates the mevalonate pathway that controls cholesterol production, cancer promotion, and bone formation. And EGCG regulates the Wnt pathway that determines the fate of developing cells and also prevents sugar-induced damage to tissues, helping to suppress their pro-aging effects.

Clinical aging studies are extremely difficult, if not impossible, to perform at this time. Our collaboration with Insilico Medicine has allowed us to develop geroprotective formulations by using artificial intelligence to study very large data sets, said Andrew G. Swick, Ph.D., senior vice president of product development and scientific affairs for Life Extension.

Scientists found these four nutrients have various complementary and reinforcing properties to influence key anti-aging pathways and combat aging factors by modulating specific biological pathways. By rejuvenating near-senescent cells and encouraging the bodys healthy process for dealing with senescent cells, Ageless Cell turns back the clock at the cellular level, said Michael A. Smith, M.D., senior health scientist for Life Extension. Alex Zhavoronkov, Ph.D., CEO of Insilico Medicine said, Together, these four natural compounds represent the beginning of the future anti-aging cocktails identified using artificial intelligence under expert human supervision.

View original post here:
Life Extension and Insilico Medicine Use AI to Develop Ageless Cell - WholeFoods Magazine

Scientists step closer to finding cause of multiple sclerosis – Medical News Today

As they find out more about the cell biology of multiple sclerosis, scientists are gradually unraveling the mysteries of the disease, although the exact causes are still unclear. Now, a new study continues this progress with a significant discovery about a new cellular mechanism. It suggests that high levels of the protein Rab32 disrupt key communications involving mitochondria. The disruption causes these "cellular batteries" to misbehave, leading to the toxic effects seen in the brain cells of people with multiple sclerosis.

The new study is the work of researchers from the University of Exeter in the United Kingdom and the University of Alberta in Canada. They report their findings in the Journal of Neuroinflammation.

Co-author Paul Eggleton, an immunologist and professor at the University of Exeter Medical School, says that multiple sclerosis can have a "devastating impact on people's lives," and yet, unfortunately, the present situation is that "all medicine can offer is treatment and therapy for the symptoms."

Multiple sclerosis (MS) is a disease in which the immune system mistakenly attacks tissue of the central nervous system - which comprises the brain, spinal cord, and optic nerve.

As the disease progresses, it destroys more and more of the fatty myelin sheath that insulates and protects the nerve fibers that send electrical messages in the central nervous system.

This destruction can lead to brain damage, vision impairment, pain, altered sensation, extreme fatigue, problems with movement, and other symptoms.

As research into the cause of MS progresses, scientists are becoming increasingly interested in the role of mitochondria - the tiny components inside cells that produce units of energy for powering the cell.

Fast facts about MS

Learn more about MS

In earlier work, the team behind the new study was the first to provide an explanation for the role of defective mitochondria in MS through clinical and laboratory experiments.

In their new investigation, the researchers study a protein called Rab32, which is known to be involved in certain mitochondrial processes.

They found that levels of Rab32 are much higher in the brains of people with MS and hardly detectable in brains of people without the disease.

They also discovered that the presence of Rab32 coincides with disruption to a communication system that causes mitochondria to malfunction, causing toxic effects in the brain cells of people with MS.

The disruption is caused by a cell compartment called the endoplasmic reticulum (ER) being too close to the mitochondria.

The ER produces, processes, and transports many compounds that are used inside and outside the cell.

The researchers note that one of the functions of the ER is to store calcium, and if the distance between the ER and mitochondria is too short, it disrupts the communication between the mitochondria and the calcium supply.

Calcium uptake into mitochondria is already known to be critical to cell functioning.

Although they did not discover what causes Rab32 levels to increase, the team believes that the problem may lie in a defect in the base of the ER.

The study could help scientists to find ways to use Rab32 as a treatment target, as well as look for other proteins that may cause similar disruptions, note the authors.

"Our exciting new findings have uncovered a new avenue for researchers to explore. It is a critical step, and in time, we hope it might lead to effective new treatments for MS."

Prof. Paul Eggleton

Learn how a new immunotherapy reversed paralysis in mouse models of MS.

Go here to read the rest:
Scientists step closer to finding cause of multiple sclerosis - Medical News Today

Global Stem Cell Therapy Market – Analysis, Technologies and Forecasts to 2021 – Increasing Demand to Develop … – Yahoo Finance

DUBLIN, April 24, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Stem Cell Therapy Market 2017-2021" report to their offering.

Research and Markets Logo

The global stem cell therapy market to grow at a CAGR of 36.52% during the period 2017-2021.

The report, Global Stem Cell Therapy Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

The latest trend gaining momentum in the market is evolution of new destinations in the development of stem cell therapies. Traditionally, the US and European countries are the key destinations for clinical trials for stem cell therapy products. However, the transformation of regulatory landscape in countries such as Japan and South Korea has made these regions as attractive destinations for the development of stem cell therapy products.

According to the report, one of the major drivers for this market is increase in federal funding in stem cell therapy. Research and clinical trials of stem cell therapy require huge investment, which many research institutes and small companies cannot afford. Therefore, many federal organizations provide funding to these institutes and small companies to help their innovative ideas in the development of stem cell therapies. Worldwide, many government organizations have noticed the importance of regenerative medicine, and thus they have allocated funds and grants in that area. For instance, in the US, the NIH and CIRM provide most of the funds.

Key vendors

Key Topics Covered:

Part 01: Executive summary

Part 02: Scope of the report

Part 03: Research Methodology

Part 04: Introduction

Part 05: Understanding of stem cell therapy

Part 06: Ethical issues and regulatory landscape

Part 07: Key clinical trials

Part 08: Market landscape

Part 09: Market segmentation by therapy

Part 10: Market segmentation by applications

Part 11: Geographical segmentation

Part 12: Market drivers

Part 13: Impact of drivers

Part 14: Market challenges

Part 15: Impact of drivers and challenges

Part 16: Market trends

Part 17: Vendor landscape

Part 18: Key vendor analysis

For more information about this report visit http://www.researchandmarkets.com/research/gdv8s6/global_stem_cell

Media Contact:

Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-stem-cell-therapy-market---analysis-technologies-and-forecasts-to-2021---increasing-demand-to-develop-effective-drugs-for-cardiology-and-degenerative-disorders---research-and-markets-300444066.html

Read more:
Global Stem Cell Therapy Market - Analysis, Technologies and Forecasts to 2021 - Increasing Demand to Develop ... - Yahoo Finance

Global CAR T Cell Therapy Market & Clinical Trials Insight 2022: 99 Car T Cell Based Therapies in Clinical Pipeline … – Yahoo Finance

DUBLIN--(BUSINESS WIRE)--

Research and Markets has announced the addition of the "Global CAR T Cell Therapy Market & Clinical Trials Insight 2022" report to their offering.

The report highlights the ongoing clinical and non-clinical advancement in the field of Car T Cell Therapy. As per report findings, the promise of CAR modified T cell therapy derives from its combined immunologic benefits and include the specificity of a targeted antibody, the ability to expand the T cell population and the potential for long term persistence to facilitate the ongoing tumor surveillance. The success in early phase trials, assess the feasibility of evaluating the treatment modality across the multiple centers and in larger patients. Currently, there are 99 CAR T Cell based therapies in clinical pipeline and most of them belong to Phase-I and Phase-I/II clinical trials.

In recent years, researchers have identified the chimeric antigen receptor as a potential target for molecular genetics to insert a new epitopes on the receptor region which allows a degree of control of the immune system. CAR T cell therapy satisfy the need to explore new and efficacious adoptive T cell therapy. The gene transfer technology could efficiently introduce the genes encoding CARs into the immune effector cells. The transferring of engineered T cells provides the specific antigen binding in a non-major histocompatibility complex.

The promise of CAR modified T cell therapy derives from its combined immunologic benefits and include the specificity of a targeted antibody, the ability to expand the T cell population and the potential for long term persistence to facilitate the ongoing tumor surveillance. The success in early phase trials, assess the feasibility of evaluating the treatment modality across the multiple centers and in larger patients.

Companies Mentioned

Key Topics Covered:

1. Chimeric Antigen Receptor (CAR) T Cell Therapy - Next Era in Immuno Oncology

2. Evolution of Chimeric Antigen Receptor (CAR) T-Cell Design

3. Principle of Chimeric Antigen Receptor Design

4. CAR T Cell Therapies Delivery Pipeline & Mechanism of Action

5. Approaches to Improve the CAR T Cell Therapy

6. Global CAR T Cell Therapy Clinical Trials for Cancer Treatment

7. Global CAR T Cell Therapies Clinical Pipeline by Company, Indication & Phase

8. Global Market Scenario of CAR T Cell Therapy

9. Global Market Size of CAR T Cell Therapy

10. Global CAR T Cell Therapy Market Dynamics

11. Global CAR T Cell Therapy Market Future Prospects

12. Competitive Landscap

For more information about this report visit http://www.researchandmarkets.com/research/3h29l7/global_car_t_cell

View source version on businesswire.com: http://www.businesswire.com/news/home/20170424006562/en/

See the article here:
Global CAR T Cell Therapy Market & Clinical Trials Insight 2022: 99 Car T Cell Based Therapies in Clinical Pipeline ... - Yahoo Finance